Intelligence Report · ~15 min read
Substance Use Disorder · Opioid Use Disorder Therapeutic Area Assessment
1 signals · 1 insights · 5 regulatory precedents
Type
Therapeutic Area AssessmentGenerated
Jul 24, 2026
Confidence
Low Confidence · 49%
Evidence
7 items
Sources
1
Executive Summary
Synthesized assessment from linked signals, findings, and evidence relationships.
Therapeutic area assessment for Substance Use Disorder · Opioid Use Disorder integrates 1 signals, 1 executive insights, and 5 regulatory precedents from the Humanexa intelligence graph. 0 portfolio assets maintain indication overlap in this area. Regulatory and competitive dynamics require cross-functional monitoring across linked entities.
Key Developments
Material intelligence events ranked by strategic relevance.
- signalJun 24, 2026
VA Study to Test Values-Based Intervention for Veterans in Buprenorphine Treatment
A new study will evaluate a brief, values-based intervention aimed at improving interpersonal functioning in Veterans undergoing early buprenorphine treatment.
View detail - regulatoryJun 24, 2026
FDA approves belzutifan with pembrolizumab for adjuvant treatment of renal cell carcinoma
Why this matters: sets a safety guidance precedent in the same sub-indication (pain) as Veterans with Opioid Use Disorder.
View detail - regulatoryJun 24, 2026
Over-The-Counter (OTC) Heartburn Treatment
There are three classes of OTC medications for the treatment of heartburn. Learn more.
View detail - regulatoryJun 24, 2026
FDA AP — BUPRENORPHINE (SUPPL)
Application ANDA211586. Sponsor: AMNEAL. Submission status: AP. Submission type: SUPPL. Active ingredients: BUPRENORPHINE.
View detail - regulatoryJun 24, 2026
FDA AP — BUPRENORPHINE (SUPPL)
Application ANDA204937. Sponsor: WATSON LABS TEVA. Submission status: AP. Submission type: SUPPL. Active ingredients: BUPRENORPHINE.
View detail - insightJun 24, 2026
Integrating Psychological Support into Buprenorphine Treatment for Veterans with Opioid Use Disorder
This study represents a significant advancement in addressing the psychological and social challenges faced by Veterans undergoing buprenorphine treatment for opioid use disorder. If successful, it could lead to the development of integrated treatment protocols that enhance overall therapeutic outcomes, which is critical for improving patient care in this demographic. Regulatory context from FDA (FDA AP — BUPRENORPHINE (SUPPL)) supports the near-term read. Assessment grounded in 14 ranked evidence items (3 high-relevance).
View detail
Strategic Implications
Portfolio and competitive decisions informed by this intelligence profile.
Executive insights surface 1 risk-calibrated assessments for portfolio review. 5 Regunera precedents provide regulatory context for pathway and timing decisions. Monitor 0 companies with active signal exposure for competitive and portfolio shifts.
Supporting Evidence
Evidence-backed items with source attribution and confidence disclosure.
FDA approves belzutifan with pembrolizumab for adjuvant treatment of renal cell carcinoma
72%Why this matters: sets a safety guidance precedent in the same sub-indication (pain) as Veterans with Opioid Use Disorder.
Source: FDA
View evidenceOver-The-Counter (OTC) Heartburn Treatment
72%There are three classes of OTC medications for the treatment of heartburn. Learn more.
Source: FDA
View evidenceFDA AP — BUPRENORPHINE (SUPPL)
72%Application ANDA211586. Sponsor: AMNEAL. Submission status: AP. Submission type: SUPPL. Active ingredients: BUPRENORPHINE.
Source: FDA
View evidenceFDA AP — BUPRENORPHINE (SUPPL)
72%Application ANDA204937. Sponsor: WATSON LABS TEVA. Submission status: AP. Submission type: SUPPL. Active ingredients: BUPRENORPHINE.
Source: FDA
View evidenceFDA AP — BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE (SUPPL)
72%Application ANDA205806. Sponsor: DR REDDYS LABS SA. Submission status: AP. Submission type: SUPPL. Review priority: STANDARD. Active ingredients: BUPRENORPHINE HYDROCHLORIDE, NALOXONE HYDROCHLORIDE.
Source: FDA
View evidenceIntegrating Psychological Support into Buprenorphine Treatment for Veterans with Opioid Use Disorder
49%This study represents a significant advancement in addressing the psychological and social challenges faced by Veterans undergoing buprenorphine treatment for opioid use disorder. If successful, it could lead to the development of integrated treatment protocols that enhance overall therapeutic outcomes, which is critical for improving patient care in this demographic. Regulatory context from FDA (FDA AP — BUPRENORPHINE (SUPPL)) supports the near-term read. Assessment grounded in 14 ranked evidence items (3 high-relevance).
Source: Humanexa Insight
View evidence
Related Intelligence
Deep links to signals, insights, companies, and assets in the Humanexa graph.
Signals
Insights
- Integrating Psychological Support into Buprenorphine Treatment for Veterans with Opioid Use Disorder
Substance Use Disorder · Opioid Use Disorder